At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMRX Immuneering Corp
Market Closed 05-22 16:00:00 EDT
5.39
+0.17
+3.26%
盘后5.35
-0.04-0.74%
19:59 EDT
High6.89Low5.29Vol10.18M
Open5.99D1 Closing5.22Amplitude30.65%
Mkt Cap348.03MTradable Cap293.28MTotal Shares64.57M
T/O62.80MT/O Rate18.70%Tradable Shares54.41M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Cencora (COR)
TIPRANKS  ·  05-22 08:40
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Cencora (COR)
Immuneering says atebimetinib-chemo trial shows 17.3-month median survival in pancreatic cancer
Reuters  ·  05-22
Immuneering says atebimetinib-chemo trial shows 17.3-month median survival in pancreatic cancer
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated With Atebimetinib Plus Chemotherapy
THOMSON REUTERS  ·  05-22
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated With Atebimetinib Plus Chemotherapy
Immuneering Corp - Only Anemia (16%) and Neutropenia (18%) Grade 3+ Adverse Events in ≥10% of Patients
THOMSON REUTERS  ·  05-22
Immuneering Corp - Only Anemia (16%) and Neutropenia (18%) Grade 3+ Adverse Events in ≥10% of Patients
Immuneering Corp - Full Data From 55 Patients to Be Presented at Asco on June 1, 2026
THOMSON REUTERS  ·  05-22
Immuneering Corp - Full Data From 55 Patients to Be Presented at Asco on June 1, 2026
Immuneering Corp - Reports 17.3-Month Median Overall Survival as of April 24, 2026 Data Cutoff
THOMSON REUTERS  ·  05-22
Immuneering Corp - Reports 17.3-Month Median Overall Survival as of April 24, 2026 Data Cutoff
Immuneering Corp - Phase 3 Mapkeeper 301 Trial Recruiting; First Patient Dosing Expected Mid-2026
THOMSON REUTERS  ·  05-22
Immuneering Corp - Phase 3 Mapkeeper 301 Trial Recruiting; First Patient Dosing Expected Mid-2026
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
GlobeNewswire  ·  05-22
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Is Maintained at Buy by Chardan Capital
Dow Jones  ·  05-20
Immuneering Is Maintained at Buy by Chardan Capital
Immuneering (IMRX) Gets a Buy from Chardan Capital
TIPRANKS  ·  05-20
Immuneering (IMRX) Gets a Buy from Chardan Capital
Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)
TIPRANKS  ·  05-18
Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)
Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)
TIPRANKS  ·  05-16
Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
Reuters  ·  05-15
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
Immuneering Q1 FY26 net loss narrows to $13.5 million
Reuters  ·  05-15
Immuneering Q1 FY26 net loss narrows to $13.5 million
Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate
Benzinga  ·  05-15
Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate
Immuneering Corp - Ends Q1 2026 With $198.6 Mln in Cash and Securities; Runway Into 2029
THOMSON REUTERS  ·  05-15
Immuneering Corp - Ends Q1 2026 With $198.6 Mln in Cash and Securities; Runway Into 2029
Immuneering Corporation Q1 Net Income USD -13.5 Million VS. Ibes Estimate USD -17.3 Million
THOMSON REUTERS  ·  05-15
Immuneering Corporation Q1 Net Income USD -13.5 Million VS. Ibes Estimate USD -17.3 Million
Press Release: Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Dow Jones  ·  05-15
Press Release: Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
TIPRANKS  ·  05-08
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
Immuneering announces updated data from Phase 2a trial for atebimetinib
TIPRANKS  ·  04-22
Immuneering announces updated data from Phase 2a trial for atebimetinib

Introduction

Company Name.
Immuneering Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Issue price:
--